BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34344012)

  • 1. Carbohydrate Antigen 19-9 Is an Invasive Malignancy Preoperative Prognostic Factor for Intraductal Papillary Mucinous Neoplasms.
    Suzuki S; Shimoda M; Shimazaki J; Oshiro Y; Nishda K; Orimoto N; Nagakawa Y; Tsuchida A
    Eur Surg Res; 2021; 62(4):262-270. PubMed ID: 34344012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnostic efficacy for predicting intraductal papillary mucinous neoplasms of the pancreas with high grade dysplasia or invasive carcinoma based on the surgery indications in different guidelines].
    Li B; Guo SW; Shi XH; Shen S; Zhang GX; Gao SZ; Pan YQ; Xu XF; Jin G
    Zhonghua Wai Ke Za Zhi; 2021 May; 59(5):359-365. PubMed ID: 33915626
    [No Abstract]   [Full Text] [Related]  

  • 3. Outcome after resection for invasive intraductal papillary mucinous neoplasia is similar to conventional pancreatic ductal adenocarcinoma.
    Holmberg M; Ghorbani P; Gilg S; Del Chiaro M; Arnelo U; Löhr JM; Sparrelid E
    Pancreatology; 2021 Oct; 21(7):1371-1377. PubMed ID: 34426077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of para-aortic lymph node status in resected pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous neoplasm - Time to consider a reclassification?
    Linder S; Holmberg M; Engstrand J; Ghorbani P; Sparrelid E
    Surg Oncol; 2022 May; 41():101735. PubMed ID: 35287096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Branch-duct intraductal papillary mucinous neoplasm (IPMN): Are cyst volumetry and other novel imaging features able to improve malignancy prediction compared to well-established resection criteria?
    Pozzi Mucelli RM; Moro CF; Del Chiaro M; Valente R; Blomqvist L; Papanikolaou N; Löhr JM; Kartalis N
    Eur Radiol; 2022 Aug; 32(8):5144-5155. PubMed ID: 35275259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invasive, mixed-type intraductal papillary mucinous neoplasm: superior prognosis compared to invasive main-duct intraductal papillary mucinous neoplasm.
    Ceppa EP; Roch AM; Cioffi JL; Sharma N; Easler JJ; DeWitt JM; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
    Surgery; 2015 Oct; 158(4):937-44; discussion 944-5. PubMed ID: 26173683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical FAP Expression Reflects
    Spektor AM; Gutjahr E; Lang M; Glatting FM; Hackert T; Pausch T; Tjaden C; Schreckenberger M; Haberkorn U; Röhrich M
    J Nucl Med; 2024 Jan; 65(1):52-58. PubMed ID: 38167622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome after surgery for invasive intraductal papillary mucinous neoplasia compared to conventional pancreatic ductal adenocarcinoma - A Swedish nationwide register-based study.
    Holmberg M; Radkiewicz C; Strömberg C; Öman M; Ghorbani P; Löhr JM; Sparrelid E
    Pancreatology; 2023 Jan; 23(1):90-97. PubMed ID: 36522260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to American Joint Committee on Cancer Stage.
    Waters JA; Schnelldorfer T; Aguilar-Saavedra JR; Chen JH; Yiannoutsos CT; Lillemoe KD; Farnell MB; Sarr MG; Schmidt CM
    J Am Coll Surg; 2011 Aug; 213(2):275-83. PubMed ID: 21601488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas.
    Kim JR; Jang JY; Kang MJ; Park T; Lee SY; Jung W; Chang J; Shin Y; Han Y; Kim SW
    J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):699-707. PubMed ID: 26178866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The carcinoembryonic antigen level in pancreatic juice and mural nodule size are predictors of malignancy for branch duct type intraductal papillary mucinous neoplasms of the pancreas.
    Hirono S; Tani M; Kawai M; Okada K; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
    Ann Surg; 2012 Mar; 255(3):517-22. PubMed ID: 22301608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological Meaning of Size of Main-Duct Dilatation in Intraductal Papillary Mucinous Neoplasm of Pancreas: Proposal of a Simplified Morphological Classification Based on the Investigation on the Size of Main Pancreatic Duct.
    Kang MJ; Jang JY; Lee S; Park T; Lee SY; Kim SW
    World J Surg; 2015 Aug; 39(8):2006-13. PubMed ID: 25894399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validating a simple scoring system to predict malignancy and invasiveness of intraductal papillary mucinous neoplasms of the pancreas.
    Shin SH; Han DJ; Park KT; Kim YH; Park JB; Kim SC
    World J Surg; 2010 Apr; 34(4):776-83. PubMed ID: 20127242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma.
    Yopp AC; Katabi N; Janakos M; Klimstra DS; D'Angelica MI; DeMatteo RP; Fong Y; Brennan MF; Jarnagin WR; Allen PJ
    Ann Surg; 2011 May; 253(5):968-74. PubMed ID: 21422912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil-to-lymphocyte Ratio as a Predictor of Malignancy of Intraductal Papillary Mucinous Neoplasms.
    Sugimachi K; Mano Y; Matsumoto Y; Nakanoko T; Uehara H; Nakashima Y; Sugiyama M; Ota M; Morita M; Toh Y
    Anticancer Res; 2021 Mar; 41(3):1663-1669. PubMed ID: 33788763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A rare case of intraductal tumor of the pancreas in which an intraductal tubulopapillary neoplasm was mixed with a widely spreading gastric-type intraductal papillary-mucinous neoplasm].
    Wakabayashi T; Shirota Y; Takeda Y; Hodo Y; Ueda Y
    Nihon Shokakibyo Gakkai Zasshi; 2024; 121(5):415-424. PubMed ID: 38735750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of invasive carcinoma in branch type intraductal papillary mucinous neoplasms of the pancreas.
    Kanno A; Satoh K; Hirota M; Hamada S; Umino J; Itoh H; Masamune A; Asakura T; Shimosegawa T
    J Gastroenterol; 2010 Sep; 45(9):952-9. PubMed ID: 20383536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of postoperative adjuvant therapy in resected invasive intraductal papillary mucinous neoplasm of the pancreas: A multicenter external validation.
    Choi M; Chong JU; Hwang HK; Seo HI; Yang K; Ryu JH; Roh Y; Kim DH; Lee JH; Lee WJ; Choi SH; Kang CM
    J Hepatobiliary Pancreat Sci; 2021 Aug; 28(8):671-679. PubMed ID: 34028187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of malignancy in main duct or mixed-type intraductal papillary mucinous neoplasms of the pancreas.
    Jung HS; Han Y; Kang JS; Sohn H; Lee M; Lee KB; Kim H; Kwon W; Jang JY
    J Hepatobiliary Pancreat Sci; 2022 Sep; 29(9):1014-1024. PubMed ID: 35451206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonoperative management of main pancreatic duct-involved intraductal papillary mucinous neoplasm might be indicated in select patients.
    Roch AM; DeWitt JM; Al-Haddad MA; Schmidt CM; Ceppa EP; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
    J Am Coll Surg; 2014 Jul; 219(1):122-9. PubMed ID: 24862887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.